GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds

Area of Science:

• Neurodegenerative diseases
• Genetics
• Pharmacology

Background:

• Disease-modifying therapies targeting alpha-synuclein are advancing into clinical trials.
• Effective patient stratification is crucial for the success of these targeted therapies.
• Alpha-synucleinopathies, including Parkinson's disease and dementia with Lewy bodies, are key targets.

Purpose of the Study:

• To highlight the necessity of alpha-synuclein-specific enrichment strategies for patient stratification.
• To demonstrate a practical approach to patient stratification using a known genetic risk factor.
• To provide a framework for stratifying patients in trials for alpha-synuclein-targeting therapies.

Main Methods:

• Review of current clinical trial landscape for alpha-synuclein therapeutics.
• Analysis of the role of the GBA gene in alpha-synucleinopathies.
• Conceptual framework for patient stratification based on genetic enrichment.

Main Results:

• The development of alpha-synuclein-targeting drugs necessitates robust patient selection methods.
• The GBA gene mutation is a significant genetic risk factor strongly linked to alpha-synuclein aggregation.
• Stratification based on GBA status can enrich patient populations likely to respond to alpha-synuclein-modifying treatments.

Conclusions:

• Patient stratification is a critical prerequisite for the clinical success of alpha-synuclein-targeting therapies.
• Leveraging genetic factors like GBA offers a viable strategy for enriching patient cohorts.
• This approach is essential for optimizing therapeutic development in Parkinson's disease and dementia with Lewy bodies.